ASX Release

30 October 2026

ASX code: PIQ

Quarterly Activities Report - FY27 Quarter One

KEY HIGHLIGHTS

Operational Highlights

- Executed an exclusive Australian distribution agreement for Promarker® portfolio with Healius Limited (ASX: HLS).
- Commenced controlled market release of Promarker®D and Promarker®Eso in Western Australia and the Northern Territory on 14 September 2026.
- Post quarter end commenced national rollout of Promarker D and Promarker Eso through Healius on 26 October 2026.
- Granted a United States patent for Promarker®Endo and IP Australia issued a notice of acceptance for the Australian patent application covering Promarker Endo.
- Post quarter end completed Promarker Endo model refinement and independent Oxford validation. Commercial availability is expected in FY27 Q3, subject to clinical deployment and applicable quality, accreditation and regulatory requirements.
- Post quarter end presented at the Ignite Investment Summit to investors in Hong Kong on 14 October 2026, outlining the Company's commercialisation strategy and portfolio progress.

Financial Highlights

- Cash outflows from operations of $1.61 million for the quarter ended 30 September 2026.
- Post quarter end received $2.0 million under the FY26 Research and Development Tax Incentive in October 2026.
- Cash and cash equivalents of $1.80 million as at 30 September 2026, representing a pro forma cash position of $3.80 million after including the subsequent receipt of the $2.0 million FY26 Research and Development Tax Incentive.

PERTH, AUSTRALIA: Proteomics International Laboratories Ltd (Proteomics International or the Company; ASX: PIQ) today releases its Appendix 4C and quarterly business update for the three months ended 30 September 2026 and subsequent to the period end.

OPERATIONAL UPDATE

Commercialisation and Distribution

The Company appointed Healius Limited (ASX: HLS) as exclusive Australian pathology distribution partner for the Promarker® portfolio under an initial three-year agreement, with a further three-year extension by mutual agreement. [ASX: 22 July 2026]

The agreement provides access to approximately 1,900 patient collection centres and established referrer relationships. Healius provides specimen collection, pathology distribution and commercial delivery. Proteomics International retains responsibility for laboratory testing, clinical reporting, scientific support, and quality and regulatory compliance. The partnership will significantly expand the potential commercial opportunity for Proteomics as it gains access to Healius' expansive, existing network.


Controlled market release of Promarker D and Promarker Eso commenced in Western Australia and the Northern Territory on 14 September. [ASX: 14 September 2026]

Post quarter end commenced national rollout of Promarker D and Promarker Eso through Healius on 26 October 2026.

The commercial roadmap targets an initial United States distributor appointment in FY27 H2. Reimbursement activities focus on clinical and health economic evidence to support future market access in Australia and the United States; approval and coverage outcomes remain uncertain.

Promarker portfolio overview and highlights

The Promarker portfolio currently comprises three core products: Promarker D, Promarker Eso and Promarker Endo. Post quarter end Promarker D and Promarker Eso are commercially available in Australia, while Promarker Endo is expected to become commercially available in Australia in FY27 Q3.



Rtqo ctmgt F

Promarker D is designed to assess the risk of diabetic kidney disease before conventional clinical indicators become apparent. Initial Australian patient pricing was set at $495 per test on a private-pay basis.

Promarker Eso

Promarker Eso is designed to assist in ruling out oesophageal adenocarcinoma in patients with chronic reflux. Initial Australian patient pricing was set at $997 per test on a private-pay basis.

Promarker Endo

The Promarker Endo test is intended to provide additional information to support clinical assessment of patients with suspected endometriosis.

Post quarter end, Proteomics completed the refinement and independent validation of the model underpinning the Promarker Endo test. The refined model was independently validated using a University of Oxford cohort, following initial development with samples from The Royal Women's Hospital in Melbourne. [ASX: 13 October 2026]

Validation sensitivity was 90% for stage IV, 84% for stages III–IV, 80% for stages II–IV and 68% for all stages combined (I–IV). These are overlapping disease-stage groupings. Specificity was 71% across each grouping, using the same 125 symptomatic controls who were surgically confirmed not to have endometriosis. The same predefined model and cut-offs were applied across all stages.

Commercial availability is expected in FY27 Q3, subject to refining the assay for clinical deployment, establishing clinician reporting and follow-up guidance, and completing applicable quality, accreditation and regulatory requirements.

A United States patent was granted for the PromarkerEndo proprietary blood test for the diagnosis of endometriosis [ASX: 8 July 2026].

IP Australia issued a notice of acceptance for the Australian patent application covering blood-based protein biomarkers for diagnosing endometriosis and guiding treatment selection. [ASX: 13 August 2026]

A second patent was granted in Japan for "Endometriosis Biomarkers" (Japanese Patent No. 7925121) and registered on 14 September 2026. It follows the Company's first Japanese patent for the technology (Japanese Patent No. 7698821), announced on 30 June 2025.

OxiDx

The strategic review of OxiDx continued to evaluate development requirements, priority applications, business models, partnerships, licensing and other commercialisation options. Further investment will be assessed against clinical evidence, commercial potential, capital requirements and strategic priorities.

Laboratory Quality and Regulatory

Activities focused on laboratory workflows and systems integration to support the Healius rollout. The Company retains responsibility for testing and reporting through its accredited laboratory infrastructure.

Investor Engagement

Post quarter end, the Company presented at the Ignite Investment Summit to investors in Hong Kong. The presentation and discussion with investors across two days covered the commercialisation strategy, the Healius rollout, updated Promarker Endo validation results and reimbursement priorities. [ASX: 14 October 2026]

FINANCIAL UPDATE

Proteomics International finished the September 2026 quarter with cash and cash equivalents of $1.8 million, compared with $3.5 million at 30 June 2026. Subsequent to quarter end, the Company received $2.0million from the Research and Development Tax Incentive (RDTI) for FY26 [ASX: 21 October 2026], providing a 30 September 2026 proforma cash balance of $3.8 million.

Net cash used in operating activities was $1.61 million for the quarter.

Operating cash flows included:

- Outflows of $0.94 million for staff and administration and corporate costs.
- Outflows of $0.7 million for research and development.
- Outflows of $0.28 million for product manufacturing, operating, advertising and marketing costs.

Based on the cash balance at quarter end and net cash used in operating activities, the Company had approximately 1.1 quarters of funding available as at 30 September 2026, as calculated in item 8.5 of the accompanying Appendix 4C. Including the $2.0m RDTI received subsequent to quarter end, this would increase to approximately 2.4 quarters of funding.

Payments to Related Parties and Their Associates

In accordance with Listing Rule 4.7C, payments to related parties and their associates included in item 6.1 of the Appendix 4C totalled $213,000 and comprised directors' fees, executive remuneration and superannuation paid under existing employment and service arrangements.

This announcement has been authorised for release by the Board of Proteomics International Laboratories Ltd.

-ENDS-

For further information please contact

David Morris
CEO and Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Jane Lowe
Investor Relations
IR Department
T: +61 411 117 774
E:jane.lowe@irdepartment.com.au

About Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd (ASX: PIQ) is a medical technology company specialising in proteomics and precision diagnostics. The Company develops and commercialises blood-based tests designed to support earlier and more precise diagnosis and risk assessment.

Proteomics International has established accredited laboratory facilities in Australia and the United States and is headquartered in Perth, Western Australia.

Forward-Looking Statements

This announcement may contain forward-looking statements regarding future events and the future performance of Proteomics International.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied.

These statements are based on information available to the Company as at the date of this announcement and are not guarantees of future performance. Except as required by law or the ASX Listing Rules, the Company undertakes no obligation to update any forward-looking statements.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Proteomics International Laboratories Ltd	
ABN	**Quarter ended ("current quarter")**
78 169 979 971	30 September 2026

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	264	264
1.2	Payments for		
	(a) research and development	(700)	(700)
	(b) product manufacturing and operating costs	(232)	(232)
	(c) advertising and marketing	(45)	(45)
	(d) leased assets	-	-
	(e) staff costs	(574)	(574)
	(f) administration and corporate costs	(366)	(366)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	36	36
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (GST)	12	12
1.9	**Net cash from / (used in) operating activities**	**(1,605)**	**(1,605)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Security deposits)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1)	(1)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (leases)	(63)	(63)
3.10	**Net cash from / (used in) financing activities**	**(64)**	**(64)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	3,500	3,500
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,605)	(1,605)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Classification | Restricted

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(64)	(64)
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**1,831**	**1,831**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	651	530
5.2	Call deposits	1180	2,970
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,831**	**3,500**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	213
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

The amount at 6.1 includes Director fees for Non-Executive Directors and salary (including superannuation) for the Managing Director.

Classification | Restricted

7.	Financing facilities *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	**-**

7.5	**Unused financing facilities available at quarter end**	-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	Estimated cash available for future operating activities	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,605)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,831
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,831
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.1

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No, the Company received a $2.0m refund in October 2026 from the Research and Development Tax Incentive (RDTI) for FY26. On a proforma cash balance of $3.8m the Company would have greater than two quarters cash per the calculation used in section 8.5.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Noting the receipt of the $2.0 million RDTI refund in October 2026, the Company continues to regularly assess its capital position and future funding requirements. The Company is actively evaluating a range of potential funding and capital management alternatives to support its ongoing operations and strategic initiatives. While these assessments remain ongoing, the Company considers that there are reasonable prospects of securing additional funding should it be required.

Classification | Restricted

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer: Yes for the reasons outlined in 8.6.1 and 8.6.2.	
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.	

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

30 October 2026

Date: .....

Board of Directors

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

Classification | Restricted